Photodynamic Therapy (PDT) using photosensitive tumor localizing drugs and laser light is undergoing extensive basic, preclinical and clinical research. The therapeutic response obtained by PDT is a product of the photosensitizer concentration in the tissue and the light it absorbs. Physiological factors such as tissue O2 content, ph, and temperature may also play a role in determining the therapeutic response. It is the objective of this Phase-II project to further develop and test a Photodynamic Therapy (PDT) dosimeter system to improve the modality. This development will include (1) further refinement of a fiber optic isotropic probe for measuring the space irradiance in-vivo, (2) increasing the sensitivity of the fiber optic probe for simultaneously measuring the fluorescence of the photosensitizing drug in-vivo, (3) correlation of the measured parameters with biological response in a standardized animal model, (4) evaluation of detecting singlet oxygen emission at 1270nm as a dosimetry monitor and (5) preliminary evaluation of the usefulness of the instrument in patients undergoing PDT treatment for recurrent chest wall metastasis of breast cancer. In Phase-III the instrument will be further standardized, and controlled clinical trials undertaken to obtain FDA approval for commercialization.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA041979-02
Application #
3506498
Study Section
(SSS)
Project Start
1986-05-01
Project End
1990-05-31
Budget Start
1988-06-15
Budget End
1989-05-31
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Pdt Systems
Department
Type
DUNS #
City
Santa Barbara
State
CA
Country
United States
Zip Code
93117